Catalytic anti-oxidative stress for osteoarthritis treatment by few-layered phosphorene. (15th December 2022)

• Record Type: Journal Article
• Authors: Zhang, Xingyu; You, Yanling; Sun, Yaying; Guo, Xiang; Han Lin, ; Zong, Ming; Shi, Jianlin
• Is Part Of: Materials today bio. Volume 17(2023)
• Publication Date: 2022-12-15
• Subjects: Phosphorene -- In-situ catalysis -- Anti-inflammatory -- Osteoarthritis -- Nanocatalytic medicine; Materials science -- Periodicals; Biomedical engineering -- Periodicals; Biomedical materials -- Periodicals; 620.1
• DOI: 10.1016/j.mtbio.2022.100462
• Languages: English
• ISSNs: 2590-0064

Abstract

Abstract: As one of the most common representations of articular cartilage damage, osteoarthritis (OA) is characterized by the apoptosis and dysfunction of chondrocytes as well as the progressive degradation of extracellular matrix, of which the main components are glycosaminoglycan and type Ⅱ collagen. Few-layered phosphorene (FLP) has been attracting great attentions in biomedical fields owing to the excellent capability of in-situ catalysis for scavenging oxidate-associated molecules, especially the reactive oxygen species (ROS) and reactive nitrogen species (RNS). Herein, FLP has been fabricated and employed for articular cartilage protection by means of deleting oxidate-associated molecules. The in vitro results show that as low as 200 ​μg/mL FLP is capable of diminishing oxidative damages on the osteoarthritic chondrocytes through the efficient elimination of ROS, H2 O2 and NO. Meanwhile, the cartilage matrix protection has also been achieved at 200 ​μg/mL FLP by the uniform restoration of glycosaminoglycan and type Ⅱ collagen. FLP enables the nanocatalytic treatment for the overloaded oxidative stress in the injured articular cartilage and represents a promising alternative for osteoarthritis therapy. Graphical abstract: Image 1